These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 10974501)
21. Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: a proton magnetic resonance spectroscopy study. Ellis CM; Lemmens G; Williams SC; Simmons A; Dawson J; Leigh PN; Chaudhuri KR Neurology; 1997 Aug; 49(2):438-44. PubMed ID: 9270574 [TBL] [Abstract][Full Text] [Related]
22. [1H-proton magnetic resonance spectroscopy in patients with multiple system atrophy and cognitive dysfunction]. Xiang X; Hou X; Sun Z; Zhou G; Tang B; Jiang H Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Jun; 40(6):639-45. PubMed ID: 26164513 [TBL] [Abstract][Full Text] [Related]
23. Topographical differences of brain iron deposition between progressive supranuclear palsy and parkinsonian variant multiple system atrophy. Han YH; Lee JH; Kang BM; Mun CW; Baik SK; Shin YI; Park KH J Neurol Sci; 2013 Feb; 325(1-2):29-35. PubMed ID: 23260321 [TBL] [Abstract][Full Text] [Related]
24. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Schulz JB; Skalej M; Wedekind D; Luft AR; Abele M; Voigt K; Dichgans J; Klockgether T Ann Neurol; 1999 Jan; 45(1):65-74. PubMed ID: 9894879 [TBL] [Abstract][Full Text] [Related]
29. [Magnetic resonance spectroscopy in Parkinson's disease and multiple system atrophy]. Aotsuka A; Shinotoh H; Hattori T Nihon Rinsho; 1997 Jan; 55(1):249-54. PubMed ID: 9014459 [TBL] [Abstract][Full Text] [Related]
30. Reduction of neuromelanin-positive nigral volume in patients with MSA, PSP and CBD. Kashihara K; Shinya T; Higaki F Intern Med; 2011; 50(16):1683-7. PubMed ID: 21841326 [TBL] [Abstract][Full Text] [Related]
31. Urinary Dysfunction in Progressive Supranuclear Palsy Compared with Other Parkinsonian Disorders. Yamamoto T; Tateno F; Sakakibara R; Furukawa S; Asahina M; Uchiyama T; Hirano S; Yamanaka Y; Fuse M; Koga Y; Yanagisawa M; Kuwabara S PLoS One; 2016; 11(2):e0149278. PubMed ID: 26886104 [TBL] [Abstract][Full Text] [Related]
32. PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes. Raffel DM; Koeppe RA; Little R; Wang CN; Liu S; Junck L; Heumann M; Gilman S J Nucl Med; 2006 Nov; 47(11):1769-77. PubMed ID: 17079809 [TBL] [Abstract][Full Text] [Related]
33. What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)? Williams DR; Lees AJ Mov Disord; 2010 Feb; 25(3):357-62. PubMed ID: 20108379 [TBL] [Abstract][Full Text] [Related]
35. The utility of susceptibility-weighted imaging for differentiating Parkinsonism-predominant multiple system atrophy from Parkinson's disease: correlation with 18F-flurodeoxyglucose positron-emission tomography. Yoon RG; Kim SJ; Kim HS; Choi CG; Kim JS; Oh J; Chung SJ; Lee CS Neurosci Lett; 2015 Jan; 584():296-301. PubMed ID: 25450142 [TBL] [Abstract][Full Text] [Related]
36. MRI evaluation of progressive supranuclear palsy: differentiation from Parkinson's disease and multiple system atrophy. Eraslan C; Acarer A; Guneyli S; Akyuz E; Aydin E; Colakoglu Z; Kitis O; Calli MC Neurol Res; 2019 Feb; 41(2):110-117. PubMed ID: 30373485 [TBL] [Abstract][Full Text] [Related]